SCHEMBL16399142

SCHEMBL16399142

N#Cc1[nH]nnc1-c1csc(-c2ccc(Cl)cc2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.49
▸ RAB9A P51151 3/20 0.49
▸ SMN1; SMN2 Q16637 3/20 0.49
▸ LMNA P02545 2/20 0.49
▸ MAPT P10636 3/20 0.45
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ CYP19A1 P11511 2/20 0.44
▸ NPC1 O15118 2/20 0.44
▸ GFER P55789 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.42
▸ CDC25A P30304 1/20 0.42
▸ CDC25B P30305 1/20 0.42
▸ CDC25C P30307 1/20 0.42
▸ ADORA1 P30542 3/20 0.41
▸ GPR55 Q9Y2T6 1/20 0.40
▸ SREBF2 Q12772 1/20 0.39
▸ ATM Q13315 1/20 0.39
▸ TP53 P04637 1/20 0.38
▸ ATP4A P20648 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18005195 0.90 RAB9A (0.49) KDM4ERAB9ASMN1; SMN2LMNAMAPT
SCHEMBL18005024 0.88 CDC25A (0.55) KDM4ERAB9ASMN1; SMN2LMNAMAPT
SCHEMBL18005017 0.87 CYP1A1 (0.35) KDM4ERAB9ASMN1; SMN2LMNAMAPT
SCHEMBL18005019 0.87 RAB9A (0.49) KDM4ERAB9ASMN1; SMN2LMNAMAPT
SCHEMBL18005984 0.87 RAB9A (0.46) KDM4ERAB9ASMN1; SMN2LMNAMAPT
SCHEMBL18005014 0.87 KDM4E (0.49) KDM4ERAB9ALMNAMAPTMEN1
SCHEMBL18005982 0.87 KMT2A (0.47) KDM4ERAB9ASMN1; SMN2LMNAMAPT
SCHEMBL16399594 0.86 EIF4E (0.48) KDM4ERAB9AMEN1KMT2ANPC1
SCHEMBL16399551 0.86 EIF4E (0.39) —
SCHEMBL18005018 0.85 CYP19A1 (0.46) LMNAMAPTCYP19A1ADORA1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4570313-A2 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2025-06-18 — — EP claimed
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 — — EP claimed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 — — US claimed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 — — US claimed
EP-4570313-A2 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2025-06-18 — — EP disclosed
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 — — EP disclosed
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 — — EP disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 — — US disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 — — US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 — — US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 — — US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 — — US disclosed
EP-3022199-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2016-05-25 — — EP disclosed
WO-2015008872-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2015-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626095-B2 Cyanotriazole compounds CS, PC, ACAT1 KDM4E 2681/4885RAB9A 4775/4885SMN1; SMN2 3834/4885
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS CS, PC, ACAT1 KDM4E 2681/4885RAB9A 4775/4885SMN1; SMN2 3834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback